ATE131070T1 - Transferrinrezeptor-spezifische antikörper - neuropharmazeutisches mittel-konjugate. - Google Patents

Transferrinrezeptor-spezifische antikörper - neuropharmazeutisches mittel-konjugate.

Info

Publication number
ATE131070T1
ATE131070T1 AT90914638T AT90914638T ATE131070T1 AT E131070 T1 ATE131070 T1 AT E131070T1 AT 90914638 T AT90914638 T AT 90914638T AT 90914638 T AT90914638 T AT 90914638T AT E131070 T1 ATE131070 T1 AT E131070T1
Authority
AT
Austria
Prior art keywords
transferrin receptor
neuropharmaceutical agent
specific antibodies
antibody
agent conjugates
Prior art date
Application number
AT90914638T
Other languages
English (en)
Inventor
Phillip Friden
Original Assignee
Alkermes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Inc filed Critical Alkermes Inc
Application granted granted Critical
Publication of ATE131070T1 publication Critical patent/ATE131070T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01007—Peroxidase (1.11.1.7), i.e. horseradish-peroxidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT90914638T 1989-09-07 1990-09-07 Transferrinrezeptor-spezifische antikörper - neuropharmazeutisches mittel-konjugate. ATE131070T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/404,089 US5154924A (en) 1989-09-07 1989-09-07 Transferrin receptor specific antibody-neuropharmaceutical agent conjugates

Publications (1)

Publication Number Publication Date
ATE131070T1 true ATE131070T1 (de) 1995-12-15

Family

ID=23598111

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90914638T ATE131070T1 (de) 1989-09-07 1990-09-07 Transferrinrezeptor-spezifische antikörper - neuropharmazeutisches mittel-konjugate.

Country Status (9)

Country Link
US (1) US5154924A (de)
EP (1) EP0490998B1 (de)
JP (1) JPH05500944A (de)
AT (1) ATE131070T1 (de)
AU (1) AU654115B2 (de)
CA (1) CA2066244A1 (de)
DE (1) DE69024057T2 (de)
ES (1) ES2080838T3 (de)
WO (1) WO1991003259A1 (de)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352447A (en) * 1987-10-05 1994-10-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotoxins for treatment of intracranial lesions and as adjunct to chemotherapy
US5792458A (en) * 1987-10-05 1998-08-11 The United States Of America As Represented By The Department Of Health And Human Services Mutant diphtheria toxin conjugates
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5527527A (en) * 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
US5268164A (en) * 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
JPH07509444A (ja) * 1991-11-26 1995-10-19 アルカーメス・インコーポレーテツド トランスフェリンセレプター特異的抗体−神経薬又は診断薬複合体の製造法
US5981194A (en) 1992-07-10 1999-11-09 University Of British Columbia Use of p97 and iron binding proteins as diagnostic and therapeutic agents
ATE191853T1 (de) * 1992-07-27 2000-05-15 Us Health Zielgerichte liposome zur blut-hirne schranke
EP0599303A3 (de) * 1992-11-27 1998-07-29 Takeda Chemical Industries, Ltd. Peptide-Konjugate
WO1995007092A1 (en) * 1993-09-10 1995-03-16 The University Of Medicine And Dentistry Of New Jersey Blood-brain barrier transporters of neurological agents
WO1995022963A1 (en) * 1994-02-28 1995-08-31 Medinova Medical Consulting Gmbh Drug targeting system, method for preparing same and its use
US5545553A (en) * 1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5817789A (en) 1995-06-06 1998-10-06 Transkaryotic Therapies, Inc. Chimeric proteins for use in transport of a selected substance into cells
AU733495B2 (en) 1996-10-28 2001-05-17 Nycomed Imaging As Improvements in or relating to diagnostic/therapeutic agents
US6331289B1 (en) 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
US20070036722A1 (en) * 1996-10-28 2007-02-15 Pal Rongved Separation processes
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
IT1291114B1 (it) 1997-03-20 1998-12-29 Angeletti P Ist Richerche Bio Varianti del fattore neurotrofico ciliare (cntf) con migliorata selettivita' al recettore, e metodo per la loro selezione
EP1261340B1 (de) 1999-07-13 2009-05-13 Alpha Research Group, LLC Zusammensetzungen und verfahren zur behandlung der parkinson-krankheit
US20020198231A1 (en) * 1999-07-13 2002-12-26 Jodi Nelson Compositions and methods for the treatment of Parkinson's disease
US20040229908A1 (en) * 1999-07-13 2004-11-18 Jodi Nelson Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias
AU6607100A (en) * 1999-07-23 2001-02-13 Regents Of The University Of California, The Anti-growth factor receptor avidin fusion proteins as universal vectors for drugdelivery
JP2003525038A (ja) * 2000-02-08 2003-08-26 ユニバーシティー オブ ブリティッシュ コロンビア 治療薬をスクリーニングするための組成物および方法
US7235397B1 (en) * 2000-04-14 2007-06-26 Gensys, Inc. Methods and compositions for culturing spirochete and treating spirochetal diseases
US6372250B1 (en) 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
WO2003013437A2 (en) * 2001-08-07 2003-02-20 University Of Delaware Compositions and methods for the prevention and treatment of huntington's disease
US20040096880A1 (en) * 2001-08-07 2004-05-20 Kmiec Eric B. Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7399613B2 (en) * 2001-10-10 2008-07-15 Neose Technologies, Inc. Sialic acid nucleotide sugars
US7265085B2 (en) * 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7179617B2 (en) 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7226903B2 (en) * 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
US7157277B2 (en) * 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
ES2411007T3 (es) * 2001-10-10 2013-07-04 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
US7297511B2 (en) * 2001-10-10 2007-11-20 Neose Technologies, Inc. Interferon alpha: remodeling and glycoconjugation of interferon alpha
US7439043B2 (en) * 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
US7265084B2 (en) * 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7125843B2 (en) * 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US8008252B2 (en) * 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7473680B2 (en) * 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
DE60336555D1 (de) 2002-06-21 2011-05-12 Novo Nordisk Healthcare Ag Pegylierte glykoformen von faktor vii
AR040778A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
US20040127409A1 (en) * 2002-11-07 2004-07-01 Milkhaus Laboratory, Inc. Method of treatment of psychological conditions by administration of nerve growth factor
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
NZ542094A (en) 2003-03-14 2008-12-24 Neose Technologies Inc Branched polymer conjugates comprising a peptide and water-soluble polymer chains
GB0306309D0 (en) * 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
PL1615945T3 (pl) 2003-04-09 2012-03-30 Ratiopharm Gmbh Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
EP1613261A4 (de) * 2003-04-09 2011-01-26 Novo Nordisk As Intrazelluläre bildung von peptidkonjugaten
JP2007523630A (ja) 2003-05-09 2007-08-23 ネオス テクノロジーズ インコーポレイテッド ヒト成長ホルモングリコシル化突然変異体の組成と調合法
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US7842661B2 (en) 2003-11-24 2010-11-30 Novo Nordisk A/S Glycopegylated erythropoietin formulations
EP1694347B1 (de) * 2003-11-24 2013-11-20 BioGeneriX AG Glycopegyliertes Erythropoetin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US20080318850A1 (en) * 2003-12-03 2008-12-25 Neose Technologies, Inc. Glycopegylated Factor Ix
US7956032B2 (en) * 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
NZ548123A (en) 2004-01-08 2010-05-28 Novo Nordisk As O-linked glycosylation of peptides
US20050202075A1 (en) * 2004-03-12 2005-09-15 Pardridge William M. Delivery of genes encoding short hairpin RNA using receptor-specific nanocontainers
KR20070008645A (ko) * 2004-05-04 2007-01-17 노보 노르디스크 헬스 케어 악티엔게젤샤프트 폴리펩티드의 ｏ-연결된 단백당형 및 그들의 제조 방법
CA2578709C (en) * 2004-06-17 2010-06-15 Virun, Inc. Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
WO2006031811A2 (en) 2004-09-10 2006-03-23 Neose Technologies, Inc. Glycopegylated interferon alpha
EP1797192A1 (de) * 2004-09-29 2007-06-20 Novo Nordisk Health Care AG Modifizierte proteine
WO2006050247A2 (en) 2004-10-29 2006-05-11 Neose Technologies, Inc. Remodeling and glycopegylation of fibroblast growth factor (fgf)
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
JP2008538181A (ja) * 2005-03-30 2008-10-16 ネオス テクノロジーズ インコーポレイテッド 昆虫細胞系において増殖させたペプチドを生産するための製造方法
WO2006121569A2 (en) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP2975135A1 (de) * 2005-05-25 2016-01-20 Novo Nordisk A/S Glykopegylierter Faktor IX
US20070105755A1 (en) * 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
MX2008002395A (es) * 2005-08-19 2008-03-18 Neose Technologies Inc Factor vii y factor viia glicopegilados.
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US8053569B2 (en) * 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
US8124095B2 (en) * 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
EP2020988B1 (de) 2006-04-28 2017-08-16 Children's Hospital Medical Center Zusammensetzungen mit fusogenen proteinen oder polypeptiden aus prosaposin zur anwendung auf transmembrane wirkstofffreisetzungssysteme
WO2007131034A1 (en) * 2006-05-03 2007-11-15 The Regents Of The University Of Michigan Pyrimidone derivatives which are modulators of heat shock protein (hsp) 70
EP2049144B8 (de) * 2006-07-21 2015-02-18 ratiopharm GmbH Glycosylierung von peptiden über o-verbundene glycosylierungssequenzen
US8759297B2 (en) * 2006-08-18 2014-06-24 Armagen Technologies, Inc. Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
EP2054521A4 (de) 2006-10-03 2012-12-19 Novo Nordisk As Verfahren zur reinigung von polypeptid-konjugate
US20080207487A1 (en) * 2006-11-02 2008-08-28 Neose Technologies, Inc. Manufacturing process for the production of polypeptides expressed in insect cell-lines
HRP20130382T1 (hr) 2007-04-03 2013-05-31 Biogenerix Ag Postupci lijeäśenja pomoä†u glikopegiliranog g-csf
WO2008137066A1 (en) * 2007-05-02 2008-11-13 The Board Of Regents Of The University Of Oklahoma Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
US20090053167A1 (en) * 2007-05-14 2009-02-26 Neose Technologies, Inc. C-, S- and N-glycosylation of peptides
CA2690611C (en) 2007-06-12 2015-12-08 Novo Nordisk A/S Improved process for the production of nucleotide sugars
AU2008282496B2 (en) 2007-07-27 2013-04-04 Armagen Technologies, Inc. Methods and compositions for increasing alpha-iduronidase activity in the CNS
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
PL2257311T3 (pl) 2008-02-27 2014-09-30 Novo Nordisk As Koniugaty cząsteczek czynnika VIII
US20100189800A1 (en) * 2009-01-23 2010-07-29 Peter Markland Continous double emulsion process for making microparticles
CA2748889A1 (en) 2009-03-18 2010-09-23 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
EP2485761B1 (de) 2009-10-09 2019-02-27 Armagen, Inc. Verfahren und zusammensetzungen für erhöhte iduronat-2-sulfatase-aktivität im zns
US8901129B2 (en) 2009-12-11 2014-12-02 Genecode As Methods of facilitating neural cell survival using GDNF family ligand (GFL) mimetics or RET signaling pathway activators
CA2818173C (en) 2010-11-30 2022-05-03 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor
AU2012346448B2 (en) 2011-12-02 2017-09-14 Armagen, Inc. Methods and compositions for increasing arylsulfatase A activity in the CNS
US10494440B2 (en) * 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
EP3088518A4 (de) 2013-12-25 2017-09-20 JCR Pharmaceuticals Co., Ltd. Durch die blut-hirn-schranke passierender, neuartiger anti-transferrin-rezeptorantikörper
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
AU2016283344B2 (en) 2015-06-24 2022-08-04 Jcr Pharmaceuticals Co., Ltd. Fusion protein containing BDNF
EA039366B1 (ru) 2015-06-24 2022-01-19 Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер
HUE057952T2 (hu) 2015-06-24 2022-06-28 Hoffmann La Roche Anti-transzferrin receptor antitestek testreszabott affinitással
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
TWI873952B (zh) 2015-10-02 2025-02-21 瑞士商赫孚孟拉羅股份公司 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
CA3052936A1 (en) 2016-12-26 2018-07-05 Jcr Pharmaceuticals Co., Ltd. Fusion protein of bdnf and anti-transferrin receptor antibody
KR102497564B1 (ko) 2016-12-26 2023-02-07 제이씨알 파마 가부시키가이샤 혈액뇌관문을 통과하는 신규한 항인간 트랜스페린 수용체 항체
CN110506055A (zh) 2017-02-17 2019-11-26 戴纳立制药公司 工程改造的转铁蛋白受体结合多肽
CA3220572A1 (en) 2021-06-11 2022-12-15 Bioarctic Ab Bispecific binding molecule
US20250257338A1 (en) 2022-04-19 2025-08-14 Jcr Pharmaceuticals Co., Ltd. Glycoprotein having reduced number of mannose-6-phosphates
KR20250162888A (ko) 2023-03-24 2025-11-19 바이오악틱 에이비 인간 트랜스페린 수용체 htfr1의 프로테아제-유사 도메인에 결합하는 이중특이적 항체
WO2025262225A1 (en) 2024-06-20 2025-12-26 Bioarctic Ab Stabilized binding molecule
WO2025262228A1 (en) 2024-06-20 2025-12-26 Bioarctic Ab Bispecific binding molecule
WO2026068519A1 (en) 2024-09-24 2026-04-02 Bioarctic Ab Ph sensitive binding molecule
WO2026068513A1 (en) 2024-09-24 2026-04-02 Bioarctic Ab Bispecific binding molecule
WO2026068532A1 (en) 2024-09-24 2026-04-02 Bioarctic Ab Bispecific binding molecule

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1564666A (en) * 1978-05-31 1980-04-10 Ng Mun Hon Heterocomplexes of interferon with immunoglobulin and pharmaceutical compositions thereof
US4292425A (en) * 1979-11-13 1981-09-29 Miles Laboratories, Inc. βGalactosyl-umbelliferone valproic acid conjugates
US4626507A (en) * 1980-09-25 1986-12-02 The Salk Institute For Biological Studies Hybridomas producing monoclonal antibodies specific for a human cell surface glycoprotein
US4631190A (en) * 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US4434156A (en) * 1981-10-26 1984-02-28 The Salk Institute For Biological Studies Monoclonal antibodies specific for the human transferrin receptor glycoprotein
US4587046A (en) * 1982-05-18 1986-05-06 The Regents Of The University Of California Drug-carrier conjugates
US4545985A (en) * 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
US4542225A (en) * 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4657853A (en) * 1984-09-14 1987-04-14 E. I. Du Pont De Nemours And Company Immunoassays utilizing covalent conjugates of polymerized enzyme and antibody
US4997913A (en) * 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
IL86009A (en) * 1987-04-10 1991-09-16 Us Health Liposome-encapsulated phosphorylated nucleosides for treatment of retroviral diseases
US4985541A (en) * 1987-04-10 1991-01-15 Zymogenetics, Inc. Novel cytotoxic protein
DE3880766D1 (de) * 1987-09-02 1993-06-09 Ciba Geigy Ag Konjugate von interferon alpha mit immunglobulinen.
DK8189A (da) * 1988-01-12 1989-07-13 Bunge Australia Antigen-antistof-konjugater, deres fremstilling og anvendelse
IE890206L (en) * 1988-02-02 1989-08-02 Akzo Nv Immunotoxins from barley toxin
IL106992A (en) * 1988-02-11 1994-06-24 Bristol Myers Squibb Co Acylhydrazone derivatives of anthracycline and methods for their preparation
EP0336383A3 (de) * 1988-04-07 1990-08-16 Takeda Chemical Industries, Ltd. Menschliches rekombinantes Lymphotoxin

Also Published As

Publication number Publication date
AU654115B2 (en) 1994-10-27
WO1991003259A1 (en) 1991-03-21
US5154924A (en) 1992-10-13
AU6445990A (en) 1991-04-08
EP0490998A1 (de) 1992-06-24
DE69024057T2 (de) 1996-06-13
JPH05500944A (ja) 1993-02-25
CA2066244A1 (en) 1991-03-08
ES2080838T3 (es) 1996-02-16
EP0490998B1 (de) 1995-12-06
DE69024057D1 (de) 1996-01-18

Similar Documents

Publication Publication Date Title
ATE131070T1 (de) Transferrinrezeptor-spezifische antikörper - neuropharmazeutisches mittel-konjugate.
Ilyas et al. IgM in a human neuropathy related to paraproteinemia binds to a carbohydrate determinant in the myelin-associated glycoprotein and to a ganglioside.
US5055289A (en) Interferon antibody therapeutic compositions having an extended serum half-life
DK0527835T3 (da) Doseringsform til afgivelse af et anti-Parkinsonmiddel
FI953529A0 (fi) Rokotteita, jotka sisältävät gangliosidi-KLH-konjugaattia ja QS-21-ainetta
EP1019072A4 (de) Verfahren zur unterstützung der differentialdiagnostik und behandlung von autistischen syndromen
AU3402295A (en) Methods and means for drug administration
EP0758843A4 (de) Modifizierte aminosäuren zur verabreichung von medikamenten
ES2137948T3 (es) Sistema avanzado de administracion de medicamentos y metodo de tratamiento de trastornos psiquiatricos, neurologicos y otros con carbamacepina.
DE69010206D1 (de) Stabilisierte protein- oder peptidkonjugate.
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
BR9306283A (pt) Processo para tratamento de degeneração com mácula l-deprenila ou sal ácido de adição da mesma
DE69736468D1 (de) Verfahren zur behandlung der ziliardyskinesie mit uridintriphosphaten und verwandten verbindungen
GR900100582A (el) Μέ?οδοι και συν?έσεις για την βελτίωση των συμπτωμάτων της σήψης.
ES2123642T3 (es) Metodo para el tratamiento del cancer por terapia conjunta con derivados de 2'-halometilideno y un agente antineoplasico especifico de fase s o fase m.
WO2006047214A2 (en) Toxins and radionuclides coupled to igf-1 receptor ligands for treatment of cancer
JPH11507389A (ja) 毒素を用いた腫瘍の治療用ワクチン
Toyka et al. Humoral factors in peripheral nerve disease
SK12782001A3 (sk) Protilátkové a chemokínové konštrukty a ich použitie pri liečbe autoimunitných chorôb
EP0525570A2 (de) TNF nachahmende anti-idiotypische Antikörper
BR9611671A (pt) Método de alvejamento de dosagens de medicamentos e de agentes terapêuticos e de outros glicosaminoglicanos (gags) para tratar de uma doença ou condição em um ser humano.
ZA933567B (en) Use of (E)-2-(p-fluorophenethyl)-3-fluoroallylamine in the treatment of Alzheimer's disease
NO961180L (no) Transdermal anordning inneholdende (E)-2-(p-fluorfenetyl)-3-fluorallylamin for behandling av Alzheimers sykdom
Aswaq et al. The homograft reaction in cancer immunology: Clinical applications
RU97104043A (ru) Способ лечения поражений сердца у детей с токсическими формами дифтерии

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties